FBC represented Check-Cap Ltd., listed on NASDAQ, in its $20.2 million follow-on underwritten public offering of units, with each unit consisting of one ordinary share (or ordinary share equivalent) and one Series C warrant to purchase one ordinary share.
H.C. Wainwright & Co. acted as sole book-running manager for the offering.
Check-Cap is a clinical-stage medical diagnostics company developing C-Scan®, an ingestible capsule-based system for preparation-free colorectal cancer screening.
